

LIBIOPSY: REFERENCES

1. Gerratana L, Davis AA, Shah AN, Lin C, Corvaja C, Cristofanilli M. Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. *Curr Treat Options Oncol*. 2019;20(8):68. Published 2019 Jun 29. doi:10.1007/s11864-019-0667-9
2. Jankowitz RC, Oesterreich S, Lee A v., Davidson NE. New strategies in metastatic hormone receptor-positive breast cancer: Searching for biomarkers to tailor endocrine and other targeted therapies. *Clinical Cancer Research*. 2017 Mar 1;23(5):1126–31.
3. Toss A, Piacentini F, Cortesi L, et al. Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. *Oncotarget*. 2018;9(60):31606-31619.
4. Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. *Lancet Oncol*. 2019;20(10):1360-1369.
5. Carausu M, Bidard FC, Callens C, et al. ESR1 mutations: a new biomarker in breast cancer. *Expert Rev Mol Diagn*. 2019;19(7):599-611.
6. Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. *Lancet Oncol*. 2019;20(10):1360-1369.
7. Gelmon KA, Cristofanilli M, Rugo HS, et al. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. *Breast J*. 2020;26(3):368-375.
8. Lianidou E, Hoon D. Circulating Tumor Cells and circulating Tumor DNA. 6th ed. Rifai N, Horvath RA, Wittwer C, editors. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*. Elsevier; 2017. 1111–1144.
9. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Vol. 6, *Cancer Discovery*. American Association for Cancer Research Inc.; 2016. p. 479–91.
10. Bardelli A, Pantel K. Liquid Biopsies, What We Do Not Know (Yet). *Cancer cell* [Internet]. 2017 Feb 13 [cited 2018 Jul 3];31(2):172–9. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S153561081730002>
11. Lianidou ES. Gene expression profiling and DNA methylation analyses of CTCs. Vol. 10, *Molecular Oncology*. Elsevier B.V.; 2016. p. 431–42.
12. Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, et al. Molecular characterization of breast cancer CTCs associated with brain metastasis. *Nature Communications*. 2017 Dec 1;8(1).
13. Jakabova A, Bielikova Z, Pospisilova E, Matkowski R, Szynglarewicz B, Staszek-Szewczyk U, et al. Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. *Breast Cancer Research and Treatment*. 2017 Dec 1;166(3):695–700.
14. Markou A, Strati A, Malamos N, Georgoulas V, Lianidou ES. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. *Clinical Chemistry*. 2011 Mar;57(3):421–30.
15. Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulas V, et al. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. *BMC Cancer*. 2011 Oct 4;11.
16. Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Vol. 134, *Critical Reviews in Oncology/Hematology*. Elsevier Ireland Ltd; 2019. p. 39–45.
17. Cristofanilli M, Pierga JY, Reuben J, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. *Crit Rev Oncol Hematol*. 2019;134:39-45.
18. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients

with operable breast cancer: Evaluation of their prognostic significance. *Journal of Clinical Oncology*. 2002 Aug 15;20(16):3404–12.

19. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. *Clinical Cancer Research*. 2008 May 1;14(9):2593–600.

20. Strati A, Kasimir-Bauer S, Markou A, Parisi C, Lianidou ES. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. *Breast Cancer Research*. 2013 Mar 7;15(2).

21. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. *Breast Cancer Research*. 2009 Jul 9;11(4).

22. Keup C, Mach P, Aktas B, Tewes M, Kolberg HC, Hauch S, et al. RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients. *Clinical Chemistry*. 2018 Jul 1;64(7):1054–62.

23. Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, et al. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. *Oncotarget*. 2016 Jul 5;7(27):41677–90.

24. Markou A, Farkona S, Schiza C, et al. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. *Clin Cancer Res*. 2014;20(22):5823-5834.19 Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulas V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. *Clinical Chemistry*. 2011 Aug;57(8):1169–77.

25. Tzanikou E, Markou A, Politaki E, et al. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. *Mol Oncol*. 2019;13(12):2515-2530. doi:10.1002/1878-0261.12540

26. Markou A, Tzanikou E, Ladas I, Makrigiorgos GM, Lianidou E. Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies. *Anal Chem*. 2019;91(20):13105-13111. doi:10.1021/acs.analchem.9b03325

27. Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. Aziz SA, editor. *PloS one*. 2013 Sep 18;8(9):e75038.

28. Bouris P, Skandalis SS, Piperigkou Z, Afratis N, Karamanou K, Aletras AJ, et al. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. *Matrix Biology*. 2015 Apr 1;43:42–60.

29. Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, et al. A digital rna signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer. *Cancer Discovery*. 2018 Oct 1;8(10).

30. Franken A, Honisch E, Reinhardt F, Meier-Stiegen F, Yang L, Jaschinski S, et al. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. *Journal of Molecular Diagnostics*. 2020 Jan 1;22(1):111–21.

31. Paolillo C, Mu Z, Rossi G, et al. Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells. *Clin Cancer Res*. 2017;23(20):6086-6093.

32. Ye Z, Wang C, Wan S, et al. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. *Eur J Cancer*. 2019;106:133-143.

33. Rossi G, Mu Z, Rademaker AW, et al. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. *Clin Cancer Res*. 2018;24(3):560-568. doi:10.1158/1078-0432.CCR-17-2092

34. O'Leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. *Nat Commun.* 2018;9(1):896. Published 2018 Mar 1. doi:10.1038/s41467-018-03215-x
35. Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. *N Engl J Med.* 2018;379(20):1926-1936.
36. O'Leary B, Cutts RJ, Liu Y, et al. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. *Cancer Discov.* 2018;8(11):1390-1403. doi:10.1158/2159-8290.CD-18-0264
37. Cristofanilli M, DeMichele A, Giorgetti C, et al. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. *Eur J Cancer.* 2018;104:21-31.
38. Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. *J Clin Oncol.* 2016;34(25):2961-2968.
39. Esteller M. Molecular origins of cancer: Epigenetics in cancer. Vol. 358, *New England Journal of Medicine.* N Engl J Med; 2008.
40. Kulis M, Esteller M. DNA Methylation and Cancer. Vol. 70, *Advances in Genetics.* Adv Genet; 2010. 27–56.
41. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Vol. 3, *Nature Reviews Genetics.* Nat Rev Genet; 2002. p. 415–28.
42. Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. Vol. 1238, *Methods in molecular biology (Clifton, N.J.).* Methods Mol Biol; 2015. p. 3–25.
43. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulas V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. *Clinical Chemistry.* 2011 Aug;57(8):1169–77.
44. Pixberg CF, Schulz WA, Stoecklein NH, Neves RPL. Characterization of DNA methylation in circulating tumor cells. Vol. 6, *Genes.* MDPI AG; 2015. p. 1053–75.
45. Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, et al. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. *Clinical biochemistry.* 2013 Feb;46(3):235–40.
46. Chimonidou M, Strati A, Malamos N, Georgoulas V, Lianidou ES. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. *Clinical chemistry.* 2013 Jan 1;59(1):270–9.
47. Stone A, Zotenko E, Locke WJ, Korbie D, Millar EKA, Pidsley R, et al. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. *Nature Communications.* 2015 Jul 14;6.
48. Tsuboi K, Nagatomo T, Gohno T, Higuchi T, Sasaki S, Fujiki N, et al. Single CpG site methylation controls estrogen receptor gene transcription and correlates with hormone therapy resistance. *Journal of Steroid Biochemistry and Molecular Biology.* 2017 Jul 1;171:209–17.
49. Marzese DM, Scolyer RA, Roqué M, Vargas-Roig LM, Huynh JL, Wilmott JS, et al. DNA Methylation and Gene Deletion Analysis of Brain Metastases in Melanoma Patients Identifies Mutually Exclusive Molecular Alterations. *Neuro-Oncology.* 2014 Nov;16(11):1499–509.
50. Sahnane N, Magnoli F, Bernasconi B, Tibiletti MG, Romualdi C, Pedroni M, et al. Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. *Clinical Epigenetics.* 2015 Dec 21;7(1).
51. Dai B, Geng L, Yu Y, Sui C, Xie F, Shen W, et al. Methylation patterns of estrogen receptor α promoter correlate with estrogen receptor α expression and clinicopathological factors in hepatocellular carcinoma. *Experimental Biology and Medicine.* 2014;239(7):883–90.
52. Kuo LT, Lu HY, Lee CC, Tsai JC, Lai HS, Tseng HM, et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in oligodendroglial tumors. *Cancer Medicine.* 2016 Aug 1;5(8):1830–9.
53. Magnani G, Furlan D, Sahnane N, Bonetti R L, Domati F, Pedroni M. Molecular Features and Methylation Status in Early Onset (≤ 40 Years) Colorectal Cancer: A Population Based, Case-Control Study *Gastroenterol Res Pract* 2015;2015:132190

54. Dou CY, Fan YC, Cao CJ, Yang Y, Wang K. Sera DNA Methylation of CDH1, DNMT3b and ESR1 Promoters as Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma. *Digestive Diseases and Sciences*. 2016 Apr 1;61(4):1130–8.
55. Kirn V, Shi R, Heublein S, Knabl J, Guenther-Biller M, Andergassen U, et al. Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients. *Journal of cancer research and clinical oncology*. 2014;140(10):1681–7.
56. Sood S, Patel FD, Ghosh S, Arora A, Dhaliwal LK, Srinivasan R. Epigenetic alteration by DNA methylation of ESR1, MYOD1 and HTERT gene promoters is useful for prediction of response in patients of locally advanced invasive cervical carcinoma treated by chemoradiation. *Clinical Oncology*. 2015;27(12):720–7.
57. Martínez-Galán J, Torres-Torres B, Núñez MI, López-Peñalver J, del Moral R, Ruiz De Almodóvar JM, et al. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. *BMC Cancer*. 2014 Feb 4;14(1).
58. de Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Vol. 10, *Molecular Oncology*. Elsevier B.V.; 2016. p. 464–74.
59. Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Vol. 51, *Critical Reviews in Clinical Laboratory Sciences*. Informa Healthcare; 2014. p. 160–71.
60. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *New England Journal of Medicine*. 2004 Aug 19;351(8):781–91.
61. Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating Tumor Cells Predict Survival in Early Average-To-High Risk Breast Cancer Patients - PubMed. *J Natl Cancer Inst*. 14AD May 15;106(5).
62. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. *The Lancet Oncology*. 2014;15(4):406–14.
63. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: A prospective study. *The Lancet Oncology*. 2012 Jul;13(7):688–95.
64. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, et al. Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients. *Journal of Clinical Oncology*. 2006 Aug 10;24(23):3756–62.
65. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Vol. 61, *Clinical Chemistry*. American Association for Clinical Chemistry Inc.; 2015. p. 112–23.
66. Marzese DM, Hirose H, Hoon DSB. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Vol. 13, *Expert Review of Molecular Diagnostics*. Expert Rev Mol Diagn; 2013. p. 827–44.
67. Mastoraki S, Strati A, Tzanikou E, et al. ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. *Clin Cancer Res*. 2018;24(6):1500-1510. doi:10.1158/1078-0432.CCR-17-1181